Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docusate + benzocaine is a combination pharmacological agent used for the treatment of chronic constipation and bowel management, particularly in patients with spinal cord injuries or neurological disorders. Docusate sodium functions as an anionic surfactant and stool softener; it reduces the surface tension of the fecal mass, allowing water and lipids to penetrate and soften the stool, thereby facilitating easier evacuation. Benzocaine is a local anesthetic of the ester type that acts by inhibiting voltage-gated sodium channels on the neuronal membrane, providing a rapid numbing effect to the rectal mucosa. This combination not only eases the passage of stool but also minimizes the discomfort and pain associated with defecation. Beijing Beiliyuan Pharmaceutical Technology Co., Ltd. is a known developer of this combination, typically formulated as a rectal solution or mini-enema for rapid onset of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on docusate + benzocaine.